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Abstract
Background: To assess safety and efficacy of tailored total lymphoid irradiation (tTLI) in cardiac transplant patients.
Methods: A total of seven patients, of which five had recalcitrant cellular cardiac allograft rejection (RCCAR),
confirmed by endomyocardial biopsies, and two had side effects of immunosuppressive drug therapy, were all
treated with tTLI. tTLI was defined by the adjustment of both the fraction interval and the final irradiation dosage
both being dependent on the patients general condition, irradiation-dependent response, and the white blood
and platelet counts. A mean dose of 6.4 Gy (range, 1.6 - 8.8 Gy) was given. Median follow-up was 7 years (range,
1.8 - 12.2 years).
Results: tTLI was well tolerated. Two patients experienced a severe infection during tTLI (pneumocystis jirovecii
pneumonia, urosepsis and generalized herpes zoster) and one patient developed a lymphoproliferative disorder
after tTLI. The rate of rejection episodes before tTLI was 0.43 episodes/patient/month and decreased to 0.02
episodes/patient/month after tTLI (P < .001). At the end of the observation time, all patients except one were alive.
Conclusions: tTLI is a useful treatment strategy for the management of RCCAR and in patients with significant side
effects of immunosuppressive drug therapy. In this series tTLI demonstrated significantly decreased rejection rates
without causing relevant treatment-related toxicity.
Background
Recalcitrant cellular cardiac allograft rejection (RCCAR)
is one of the remaining unsolved problems after heart
transplantation (HTx). In case of RCCAR, aggressive
up-regulation or adaptation of immunosupression is
required, taking additional toxicity into account [1,2],
however, without being sufficient enough to control the
rejection process. Total lymphoid irradiation (TLI) for
the treatment of RCCAR has been established for over
two decades with several published reports demonstrat-
ing safety and efficacy of this technique [2-18]. However,
little is known about the long term effects after TLI
[12,17]. This study reports on the long-term outcome of
seven patients after HTx who received tailored TLI
(tTLI) with a median follow-up of 7 years.
Methods
Patients
Five patients with RCCAR (defined as a rejection grade
of IIIA in at least three consecutive endomyocardial
biopsies (EMBs) as defined by the International Society
for Heart and Lung Transplantation (ISHLT) criteria
[19]) and two patients with severe side effects to immu-
nosuppressive drug treatment were treated by tTLI
between February 1996 and January 2006. All patients
who underwent HTx at the Swiss Cardiovascular Cen-
ter, Inselspital, Bern University Hospital received main-
tenance immunosuppressive therapy with cyclosporine
(n = 6), tacrolimus (n = 3), sirolimus (n = 4), prednisone
(n = 7), mycophenolic mofetil (n = 5) or azathioprine (n
= 4). One patient received a murine antihuman mature
T-cell monoclonal antibody (OKT3) for a total of 9
days, 3 weeks prior to tTLI, because of ongoing rejec-
tion. All patients received as induction a polyclonal
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therapy with rATG (Fresenius) during the first 5 days
after HTx. Patients were analyzed retrospectively. This
study was performed in accordance with the standards
of the local ethics committee and with the Helsinki
Declaration.
Radiation therapy
The TLI was performed tailored as previously described
[9]. Briefly, patients were treated by three separate fields
to encompass all major lymph node bearing areas. A
supradiaphragmatic mantle field, a periaortic and splenic
field and a pelvic field with inferior extension were used
in two patients. The remaining five patients received a
supradiaphragmatic mantle field and a inverted Y-field.
The non-lymphoid tissue was appropriately shielded in
all fields. All fields were treated concurrently on a linear
accelerator by an anterior/posterior opposed technique
with 6 and 15 MV photons. One patient was treated
with a Cobalt 60 source. The prescribed dose was 8 Gy
delivered in individual twice weekly 0,8 Gy fractions
(calculated midplane dose at central ray). tTLI was per-
formed on a Monday/Thursday or Tuesday/Friday sche-
dule. A control EMB was performed after 2 - 4
fractions. The final decision regarding the dosing was
based on the clinical state (e.g. infection), the irradia-
tion-dependent response (efficacy) as well as on the
white blood count (WBC) and/or platelet count (Plts)
on the day of or one day before planned tTLI. In general
tTLI was withheld for a total WBC less than 2.7 thou-
sand/mm3 (or total granulocyte count less than 1.5
thousand/mm3) or Plts less than 125 thousand/mm3 or
if Plts were rapidly decreasing.
Statistical analysis
Descriptives include absolute and relative frequencies for
categorical variables and the mean and standard devia-
tion for quantitative variables. The primary objective of
this study was to analyze safety and efficacy of tTLI.
Secondary objective was to assess long-term survival
and toxicity. A severe infection was defined as requiring
hospitalisation and/or intravenous antibiotics.
All available WBC, Plts and haemoglobin (Hb) data
were collected and analyzed from the time of HTx until
1 year after tTLI. All post-transplant rejection and infec-
tion episodes were recorded beginning right after HTx
and ending at the end of the follow-up period for each
patient. The analysis of tTLI rejection rates was based
on calculating the proportion of positive biopsies before
and after tTLI and done using an extension of general-
ized linear models for binomially distributed data using
the identity link. Statistical significance was considered
on a two-sided level of a = 0.05.
The calculations were performed with the Statistical
Analysis Systems (SAS) package (SAS Institute, Cary,
NC, USA, version 9.1).
Results
Patients
Patient characteristics are summarized in Table 1. Four
patients were male, three were female. Median age at
HTx was 47 years (range, 19 - 62 years). After HTx and
before tTLI patients had undergone a median of 14
EMBs (range, 7 - 37 EMBs) which detected a median of
5 rejections graded IIIA (range, 3 - 12 rejections). Med-
ian time from HTx to TLI was 8.8 months (range, 1.6 -
36 months). Prior to tTLI five patients had a history of
at least one severe infection. Three patients had cytome-
galovirus infection. One patient had pneumocystis jiro-
vecii pneumonia and one year later generalized herpes
zoster. Another patient had gram-negative sepsis. All
infections resolved after therapy with appropriate anti-
biotics. The mean dose was 6.4 Gy (range, 1.6 - 8.8 Gy)
with the mean total tTLI duration being 44.6 days
(range, 3 - 67 days). During tTLI a median of 4 EMBs
were performed (range, 1 - 6 EMBs). In one patient
tTLI was discontinued because of leukocytopenia and
thrombocytopenia and continued after 1.5 months. In
one patient tTLI was discontinued as EMBs revealed no
evidence of rejection. However one month later tTLI
was again required for reoccurrence of rejection (Table
1). Regarding the immunosuppressive drug therapy dur-
ing tTLI, cyclosporine was continued in 4/6 patients,
tacrolimus in 2/3 patients, sirolimus in 2/4 patients,
mycophenolic mofetil in 3/5 patients and azathioprine
in 3/4 patients.
Evaluation of Safety
General side effects during tTLI were mild and limited to
fatigue and epigastric pain. Transient bone marrow sup-
pression occurred in all patients. Three patients experi-
enced transient leukocytopenia of < 3.5 thousand/mm3
(range, 1.4 - 3.1 thousand/mm3) and five patients experi-
enced transient thrombocytopenia of < 140 thousand/
mm3 (range, 68 - 130 thousand/mm3). The median time
to the nadir of WBC, Plts and Hb was 1.5 months, 0.8
months and 0.5 months with the mean nadir values being
4.1 thousand/mm3 (range, 2.1 - 10.2 thousand/mm3),
123.4 thousand/mm3 (range, 68 - 241 thousand/mm3) and
95.9 gramm/litre (range, 75 - 116, gram/litre), respectively.
Virtually, all bone marrow functions recovered within the
three months post-tTLI (Figure 1). During tTLI only two
patients suffered from severe infection. One patient with
leukocytopenia experienced pneumocystis jirovecii pneu-
monia and urosepsis and another patient suffered from
generalized herpes zoster. All infections were successfully
treated. Further, there were no deaths observed during or
immediately following the tTLI. However, one patient died
almost 5 years after HTx and 1.9 years after completion of
tTLI because of graft coronary artery disease, all other
patients were alive at the end of follow-up. One patient
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developed post-transplant lymphoproliferative disorder 5
months after HTx and 2.4 months after completion of
tTLI. This patient had undergone OKT3 treatment prior
to the tTLI.
Evaluation of Efficacy
The rejection episodes before, during and after tTLI are
summarized in Table 2.
The rate of rejection episodes before tTLI was 0.43
episodes/patient/month (95% confidence interval [CI]:
0.31 - 0.58) and decreased to 0.02 episodes/patient/
month after tTLI (95% CI: 0.01 - 0.034; P < .001). Dur-
ing the 4 months after tTLI none of the seven patients
had further rejection episodes. In the long-term perspec-
tive, treatment with tTLI resulted in a decrease of rejec-
tion episodes by 28.6% (95% CI: 20.1 - 37.1% decrease).
The median time from tTLI to the first subsequent
rejection episode was 2.4 years. On average, patients
have remained free from acute rejection for 4.1 years
(range, 1.4 - 7.8 years).
Discussion
This study describes long-term safety and efficacy of
tTLI in patients who have experienced RCCAR or toxi-
city of immunosuppressive drug therapy after HTx. In
accordance with the literature, describing mainly a non-
tailored approach, tTLI was shown to effectively reduce
the rejection rate without major treatment related toxi-
city or infections after a median follow-up of 7 years.
Potential long-term risks of tTLI include radiation-
induced cardiomyopathy and graft coronary artery dis-
ease [17]. The patient who had died from graft coronary
artery disease in our series had undergone AB0 mis-
matched HTx, as previously described [20]. In our series
one patient developed a post-transplant lymphoproli-
ferative disorder after he had received OKT3 treatment
three weeks prior to the tTLI. The post-transplant lym-
phoproliferative disorder occurred 2.4 months after
completion of tTLI which was diagnosed as an Epstein
B Virus (EBV) associated extranodal B-cell
lymphoproliferative disease located in the left lung.
OKT3 treatment has been shown to be associated with
an increased incidence of lymphoproliferative diseases
[21,22]. There however remains a possibility that the
lymphoproliferative disorder was attributable to the
increased immunosuppression achieved by tTLI. The
actuarial risk for post-transplant lymphoproliferative dis-
order at 5-years after TLI was described to be 9% [23].
It has been demonstrated by others that mTOR-inhibi-
tion (S6 kinase pathway), decreases the apoptotic thresh-
old. This may lead to a hypersensitivity of tissues to
radiotherapy in patients treated with an mTOR-inhibitor
[24,25]. Since a significant proportion of HTx patients
are treated with mTOR inhibitors today, the interaction
between mTOR-inhibition and tTLI is an important
issue. However, in vitro observations were based on
anti-cancer radiation doses, as a consequence the impact
of mTOR-inhibition together with the relative low radia-
tion dose used in TLI may not be of clinical importance.
In accordance, four of our patients were treated with
sirolimus prior to tTLI two of which continued siroli-
mus during tTLI. In our study there was no difference
in WBC or Plts in the patients who received tTLI in
combination with sirolimus compared to the patients
who received tTLI without sirolimus. Nevertheless, if
tTLI is performed in patients on mTOR-inhibitors, care-
ful monitoring is still warranted. The main limitation of
this study is that it is a retrospective analysis of a rela-
tively small patient cohort with individually tailored
immunosuppressive drug treatment. Our experience has
however demonstrated an acceptable safety profile and
good efficacy of tTLI which we only instigate in patients
with RCCAR already on aggressive immunosuppressive
drug treatment or those who cannot tolerate these
newer agents (tacrolimus, mycophenolic mofetil and
mTOR-inhibitors). We have also demonstrated the feasi-
bility of combined treatment with tTLI and the newer
immunosuppressive drugs but recommend careful clini-
cal monitoring.
Table 1 Patient characteristics
Patient Gender Age at HTx
(years)
Dx at HTx Interval between HTx and
tTLI (months)
Duration of tTLI
(days)
Number of tTLI
courses
tTLI dose
(Gy)
Follow-up
(years)
1 Male 34 DCMP 10.7 67 2 4 + 4.8* 7.0
2 Female 57 HOCMP 36 48 1 6.4 5.2
3 Female 43 Myocarditis 2.7 3 1 1.6 1.8
4 Male 19 CHD 33.6 43 1 8 1.9
5 Male 47 DCMP 1.6 27 1 4.8 11.7
6 Female 62 CVD 2.4 57 2 1.6 + 6.4+ 12.2
7 Male 55 CAD 8.8 67 1 8 10.3
Abbreviations: HTx = heart transplantation; Dx at HTx = diagnosis leading to heart transplantation; DCMP = dilatative cardiomyopathia; HOCMP = hypertrophic
obstructive cardiomyopathia; CHD = congenital heart disease; CVD = cardiac valvular disease; CAD = coronary artery disease; tTLI = tailored total lymphoid
irradiation. * Second tTLI was initiated 1.5 months after the first one or 12.5 months after HTx. +Second tTLI was initiated 1 month after the first one or 3.5
months after HTx.
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Figure 1 White blood count (a), platelet count (b) and haemoglobin values (c) before, during (lowest value observed during tTLI) and
1, 3, 6, and 12 months after tTLI. Boxes represent 25% and 75% percentiles. Circles indicate outlier, asterisks indicate extreme values.
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Conclusion
Based on our center’s experience, tTLI is a useful treat-
ment strategy with acceptable safety and good efficacy
for both management of RCCAR and for the treatment
of patients with limited tolerance to their immunosup-
pressive drugs after HTx.
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